REGENXBIO Faces Class Action Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy RGNX?
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against REGENXBIO for violations of securities laws, concerning securities purchases from February 9, 2022, to January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that REGENXBIO made false and misleading statements regarding its product candidate RGX-111, concealing negative efficacy and safety data, which led to significant investor losses upon the revelation of the truth.
- Market Reaction: Following the disclosure of the true situation regarding RGX-111, investor losses increased significantly, highlighting the company's major missteps in information disclosure that could adversely affect its future stock performance.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to investor rights and its expertise in securities litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.410
Low
19.00
Averages
29.71
High
45.00
Current: 8.410
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regenxbio vs. Sarepta Patent Lawsuit Reinstated
- Lawsuit Reinstatement: The U.S. Court of Appeals has reinstated the patent lawsuit between Regenxbio and Sarepta regarding Sarepta's DMD treatment Elevidys, marking a new legal hurdle for Sarepta that could impact its market performance.
- Damages Request: Regenxbio and the University of Pennsylvania are seeking over $900 million in damages in the lawsuit, which could place significant financial pressure on Sarepta, especially amid ongoing regulatory scrutiny.
- Safety Concerns: Elevidys raised safety concerns in 2025 following the deaths of two patients, prompting Sarepta to develop a risk mitigation strategy to resume shipments to non-ambulatory patients, potentially affecting market confidence and sales forecasts.
- Market Sentiment: On Stocktwits, retail sentiment around RGNX and SRPT stocks trended bearish, with RGNX shares gaining 11% over the past year while SRPT stock plummeted 83%, reflecting market uncertainty regarding Sarepta's future prospects.
See More
REGENXBIO Faces Class Action Lawsuit Reminder
- Class Action Initiated: Robbins LLP reminds all investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, that a class action lawsuit has been filed, alleging the company misled investors regarding the efficacy of its drug candidate RGX-111.
- FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 due to preliminary findings of a CNS tumor in a trial participant, significantly undermining investor confidence in the company's prospects.
- Stock Price Volatility: Following the FDA's announcement, REGENXBIO's stock plummeted from $13.41 per share to $11.01 on January 28, 2026, marking a 17.8% decline in a single day, reflecting market concerns about the company's future.
- Investor Rights Protection: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 14, 2026, with Robbins LLP offering contingency fee representation to ensure shareholder rights are protected.
See More
REGENXBIO Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against REGENXBIO for violations of securities laws, concerning securities purchases from February 9, 2022, to January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that REGENXBIO made false and misleading statements regarding its product candidate RGX-111, concealing negative efficacy and safety data, which led to significant investor losses upon the revelation of the truth.
- Market Reaction: Following the disclosure of the true situation regarding RGX-111, investor losses increased significantly, highlighting the company's major missteps in information disclosure that could adversely affect its future stock performance.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to investor rights and its expertise in securities litigation.
See More
Federal Appeals Court Reverses Sarepta's Patent Victory
- Patent Dispute Reversal: The U.S. Court of Appeals for the Federal Circuit overturned a Delaware federal court ruling favoring Sarepta in its patent dispute with Regenxbio, necessitating further proceedings that could impact Sarepta's market outlook for its Duchenne muscular dystrophy treatment, Elevidys.
- Patent Technology Context: The contested patent, 10,526,617, pertains to Regenxbio's adeno-associated virus gene delivery platform, with Regenxbio alleging that Sarepta's use of this patent in Elevidys production could expose Sarepta to legal and financial risks if the ruling is unfavorable.
- University Involvement: The University of Pennsylvania, as a co-plaintiff holding an exclusive license to the patent, underscores the importance of intellectual property protection in the biotech sector, potentially affecting future collaborations and technology transfers.
- Market Reaction Potential: This ruling may lead to stock price volatility for Regenxbio, especially in light of FDA scrutiny over its gene therapies, prompting investors to monitor the implications of the upcoming proceedings on both companies' stock valuations.
See More
Faruqi & Faruqi Investigates Potential Claims Against REGENXBIO
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against REGENXBIO, particularly for investors who purchased securities between February 9, 2022, and January 27, 2026, highlighting a commitment to protecting investor rights.
- Investor Contact Information: The firm encourages affected investors to reach out directly to partner Josh Wilson, providing contact numbers 877-247-4292 and 212-983-9330, aiming to assist investors in understanding their legal rights and taking necessary actions.
- Class Action Reminder: Faruq & Faruqi reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against REGENXBIO, emphasizing the importance of timely action.
- Potential Market Impact: This investigation may negatively affect REGENXBIO's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Notice to REGENXBIO Shareholders Regarding Class Action
- Shareholder Action Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased REGENXBIO (NASDAQ:RGNX) shares between February 9, 2022, and January 27, 2026, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations Overview: The complaint alleges that REGENXBIO misled investors about the development of its RGX-111 gene therapy by providing false and misleading information while concealing significant adverse facts regarding the therapy's efficacy and safety.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 after an intraventricular CNS tumor was found in a trial participant, causing the stock price to plummet 17.8% in one day, from $13.41 to $11.01 per share.
- Registration Deadline: Shareholders must register for this class action by April 14, 2026, and will receive status updates throughout the case lifecycle, with no cost or obligation to participate.
See More
Regenxbio vs. Sarepta Patent Lawsuit Reinstated
- Lawsuit Reinstatement: The U.S. Court of Appeals has reinstated the patent lawsuit between Regenxbio and Sarepta regarding Sarepta's DMD treatment Elevidys, marking a new legal hurdle for Sarepta that could impact its market performance.
- Damages Request: Regenxbio and the University of Pennsylvania are seeking over $900 million in damages in the lawsuit, which could place significant financial pressure on Sarepta, especially amid ongoing regulatory scrutiny.
- Safety Concerns: Elevidys raised safety concerns in 2025 following the deaths of two patients, prompting Sarepta to develop a risk mitigation strategy to resume shipments to non-ambulatory patients, potentially affecting market confidence and sales forecasts.
- Market Sentiment: On Stocktwits, retail sentiment around RGNX and SRPT stocks trended bearish, with RGNX shares gaining 11% over the past year while SRPT stock plummeted 83%, reflecting market uncertainty regarding Sarepta's future prospects.
See More
REGENXBIO Faces Class Action Lawsuit Reminder
- Class Action Initiated: Robbins LLP reminds all investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, that a class action lawsuit has been filed, alleging the company misled investors regarding the efficacy of its drug candidate RGX-111.
- FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 due to preliminary findings of a CNS tumor in a trial participant, significantly undermining investor confidence in the company's prospects.
- Stock Price Volatility: Following the FDA's announcement, REGENXBIO's stock plummeted from $13.41 per share to $11.01 on January 28, 2026, marking a 17.8% decline in a single day, reflecting market concerns about the company's future.
- Investor Rights Protection: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 14, 2026, with Robbins LLP offering contingency fee representation to ensure shareholder rights are protected.
See More
REGENXBIO Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against REGENXBIO for violations of securities laws, concerning securities purchases from February 9, 2022, to January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that REGENXBIO made false and misleading statements regarding its product candidate RGX-111, concealing negative efficacy and safety data, which led to significant investor losses upon the revelation of the truth.
- Market Reaction: Following the disclosure of the true situation regarding RGX-111, investor losses increased significantly, highlighting the company's major missteps in information disclosure that could adversely affect its future stock performance.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to investor rights and its expertise in securities litigation.
See More
Federal Appeals Court Reverses Sarepta's Patent Victory
- Patent Dispute Reversal: The U.S. Court of Appeals for the Federal Circuit overturned a Delaware federal court ruling favoring Sarepta in its patent dispute with Regenxbio, necessitating further proceedings that could impact Sarepta's market outlook for its Duchenne muscular dystrophy treatment, Elevidys.
- Patent Technology Context: The contested patent, 10,526,617, pertains to Regenxbio's adeno-associated virus gene delivery platform, with Regenxbio alleging that Sarepta's use of this patent in Elevidys production could expose Sarepta to legal and financial risks if the ruling is unfavorable.
- University Involvement: The University of Pennsylvania, as a co-plaintiff holding an exclusive license to the patent, underscores the importance of intellectual property protection in the biotech sector, potentially affecting future collaborations and technology transfers.
- Market Reaction Potential: This ruling may lead to stock price volatility for Regenxbio, especially in light of FDA scrutiny over its gene therapies, prompting investors to monitor the implications of the upcoming proceedings on both companies' stock valuations.
See More
Faruqi & Faruqi Investigates Potential Claims Against REGENXBIO
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against REGENXBIO, particularly for investors who purchased securities between February 9, 2022, and January 27, 2026, highlighting a commitment to protecting investor rights.
- Investor Contact Information: The firm encourages affected investors to reach out directly to partner Josh Wilson, providing contact numbers 877-247-4292 and 212-983-9330, aiming to assist investors in understanding their legal rights and taking necessary actions.
- Class Action Reminder: Faruq & Faruqi reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against REGENXBIO, emphasizing the importance of timely action.
- Potential Market Impact: This investigation may negatively affect REGENXBIO's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Notice to REGENXBIO Shareholders Regarding Class Action
- Shareholder Action Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased REGENXBIO (NASDAQ:RGNX) shares between February 9, 2022, and January 27, 2026, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations Overview: The complaint alleges that REGENXBIO misled investors about the development of its RGX-111 gene therapy by providing false and misleading information while concealing significant adverse facts regarding the therapy's efficacy and safety.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 after an intraventricular CNS tumor was found in a trial participant, causing the stock price to plummet 17.8% in one day, from $13.41 to $11.01 per share.
- Registration Deadline: Shareholders must register for this class action by April 14, 2026, and will receive status updates throughout the case lifecycle, with no cost or obligation to participate.
See More
